Compare VVOS & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | PHIO |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 14.6M |
| IPO Year | 2020 | 2011 |
| Metric | VVOS | PHIO |
|---|---|---|
| Price | $1.31 | $1.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.25 | ★ $10.67 |
| AVG Volume (30 Days) | 109.4K | ★ 306.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,031,000.00 | N/A |
| Revenue This Year | $31.42 | N/A |
| Revenue Next Year | $49.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.91 | N/A |
| 52 Week Low | $1.09 | $0.81 |
| 52 Week High | $7.40 | $4.19 |
| Indicator | VVOS | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 55.82 |
| Support Level | N/A | $1.11 |
| Resistance Level | $1.50 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 64.38 | 68.18 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.